Association of Hospital Procedural Volume With Outcomes of Left Ventricular Assist Device Placement.


Journal

Journal of cardiac failure
ISSN: 1532-8414
Titre abrégé: J Card Fail
Pays: United States
ID NLM: 9442138

Informations de publication

Date de publication:
11 2023
Historique:
received: 06 02 2023
revised: 19 05 2023
accepted: 11 06 2023
medline: 20 11 2023
pubmed: 8 7 2023
entrez: 7 7 2023
Statut: ppublish

Résumé

With the advancement in device technology, the use of durable left ventricular assist devices (LVADs) has increased significantly in recent years. However, there is a dearth of evidence to conclude whether patients who undergo LVAD implantation at high-volume centers have better clinical outcomes than those receiving care at low- or medium-volume centers. We analyzed the hospitalizations using the Nationwide Readmission Database for the year 2019 for new LVAD implantation. Baseline comorbidities and hospital characteristics were compared among low- (1-5 procedures/year), medium- (6-16 procedures/year) and high-volume (17-72 procedures/year) hospitals. The volume/outcome relationship was analyzed using the annualized hospital volume as a categorical variable (tertiles) as well as a continuous variable. Multilevel mixed-effect logistic regression and negative binomial regression models were used to determine the association of hospital volume and outcomes, with tertile 1 (low-volume hospitals) as the reference category. A total of 1533 new LVAD procedures were included in the analysis. The inpatient mortality rate was lower in the high-volume centers compared with the low-volume centers (9.04% vs 18.49%, aOR 0.41, CI0.21-0.80; P = 0.009). There was a trend toward lower mortality rates in medium-volume centers compared with low-volume centers; however, it did not reach statistical significance (13.27% vs 18.49%, aOR 0.57, CI0.27-1.23; P = 0.153). Similar results were seen for major adverse events (composite of stroke/transient ischemic attack and in-hospital mortality). There was no significant difference in bleeding/transfusion, acute kidney injury, vascular complications, pericardial effusion/hemopericardium/tamponade, length of stay, cost, or 30-day readmission rates between medium- and high-volume centers compared to low-volume centers. Our findings indicate lower inpatient mortality rates in high-volume LVAD implantation centers and a trend toward lower mortality rates in medium-volume LVAD implantation centers compared to lower-volume centers.

Sections du résumé

BACKGROUND
With the advancement in device technology, the use of durable left ventricular assist devices (LVADs) has increased significantly in recent years. However, there is a dearth of evidence to conclude whether patients who undergo LVAD implantation at high-volume centers have better clinical outcomes than those receiving care at low- or medium-volume centers.
METHODS
We analyzed the hospitalizations using the Nationwide Readmission Database for the year 2019 for new LVAD implantation. Baseline comorbidities and hospital characteristics were compared among low- (1-5 procedures/year), medium- (6-16 procedures/year) and high-volume (17-72 procedures/year) hospitals. The volume/outcome relationship was analyzed using the annualized hospital volume as a categorical variable (tertiles) as well as a continuous variable. Multilevel mixed-effect logistic regression and negative binomial regression models were used to determine the association of hospital volume and outcomes, with tertile 1 (low-volume hospitals) as the reference category.
RESULTS
A total of 1533 new LVAD procedures were included in the analysis. The inpatient mortality rate was lower in the high-volume centers compared with the low-volume centers (9.04% vs 18.49%, aOR 0.41, CI0.21-0.80; P = 0.009). There was a trend toward lower mortality rates in medium-volume centers compared with low-volume centers; however, it did not reach statistical significance (13.27% vs 18.49%, aOR 0.57, CI0.27-1.23; P = 0.153). Similar results were seen for major adverse events (composite of stroke/transient ischemic attack and in-hospital mortality). There was no significant difference in bleeding/transfusion, acute kidney injury, vascular complications, pericardial effusion/hemopericardium/tamponade, length of stay, cost, or 30-day readmission rates between medium- and high-volume centers compared to low-volume centers.
CONCLUSION
Our findings indicate lower inpatient mortality rates in high-volume LVAD implantation centers and a trend toward lower mortality rates in medium-volume LVAD implantation centers compared to lower-volume centers.

Identifiants

pubmed: 37419409
pii: S1071-9164(23)00233-6
doi: 10.1016/j.cardfail.2023.06.017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1531-1538

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Auteurs

Shazib Sagheer (S)

Division of Cardiology, University of New Mexico Health Sciences Center, Albuquerque, NM; Division of Interventional Cardiology, Newark Beth Israel Medical Center, Newark, NJ, USA. Electronic address: Shazibcheema@gmail.com.

Abdul Mannan Khan Minhas (AMK)

Division of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.

Syeda Humna Zaidi (SH)

Karachi Medical and Dental College, Karachi, Pakistan.

Ishan Shah (I)

Division of Cardiology, University of New Mexico Health Sciences Center, Albuquerque, NM; Division of Interventional Cardiology, Newark Beth Israel Medical Center, Newark, NJ, USA.

Keerat Rai Ahuja (KR)

Department of Cardiology, Reading Hospital-Tower Health, Reading, PA, USA.

Satish Kumar Ahuja (SK)

Department of Internal Medicine, Reading Hospital-Tower Health, Reading, PA, USA.

Salik Nazir (S)

The Aga Khan University, Karachi, Pakistan, and Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

Khawaja M Talha (KM)

Division of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.

Sourbha S Dani (SS)

Division of Cardiology, Lahey Hospital and Medical Center, Burlington, MA, USA.

Marat Fudim (M)

Division of Cardiology, Duke University Medical Center, Durham, NC, USA; Duke Clinical Research Institute, Durham, NC, USA.

Dmitry Abramov (D)

Department of Medicine, Division of Cardiology, Loma Linda University Medical Center, Loma Linda, CA, USA.

Salim S Virani (SS)

The Aga Khan University, Karachi, Pakistan, and Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.

Najam Wasty (N)

Division of Interventional Cardiology, Newark Beth Israel Medical Center, Newark, NJ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH